Immunohistochemical profile of NF-κB/p50, NF-κB/p65, MMP-9, MMP-2, and u-PA in experimental cervical spondylotic myelopathy

Spine

Volumn 38, Issue 1, 2013, Pages 4-10

  Karadimas, Spyridon K ^a   Klironomos, George ^a,b   Papachristou, Dionysios J ^b,c   Papanikolaou, Sofia ^b   Papadaki, Eleni ^b   Gatzounis, George ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

cervical spondylotic myelopathy; glial cells; MMP 2; MMP 9; neurons; NF B; spinal cord; u PA

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CERVICAL SPONDYLOTIC MYELOPATHY; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; GLIA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CERVICAL VERTEBRAE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B P50 SUBUNIT; RABBITS; SPINAL CORD DISEASES; SPONDYLOSIS; TRANSCRIPTION FACTOR RELA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84871977280     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e318261ea6f     Document Type: Article

References (51)

1. Fehlings MG, Skaf G. A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Spine 1998; 23: 2730-7. (Pubitemid 29013985)
2. Nakamura I, Ikegawa S, Okawa A, et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999; 104: 492-7. (Pubitemid 29370925)
3. Lee CH, Jeon YT, Kim SH, et al. NF-κ B as a potential molecular target for cancer therapy. Biofactors 2007; 29: 19-35. (Pubitemid 46985299)
4. Baldwin AS, Jr. Series introduction: the transcription factor NF-κ B and human disease. J Clin Invest 2001; 107: 3-6.
5. Kim HJ, Hawke N, Baldwin AS. NF-κ B and IKK as therapeutic targets in cancer. Cell Death Differ 2001; 13: 738-47.
6. Matrisian LM. The matrix-degrading metalloproteinases. Bio Essays 1992; 14: 455-63.
7. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis, and metastasis. Trends Cell Biol 2001; 11: S37-43.
8. Sternlicht MD, Werb Z. How MMPs regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
9. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-11. (Pubitemid 33676585)
10. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37-69. (Pubitemid 40720240)
11. Rosenberg GA, Dencoff JE, McGuire PG, et al. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 1994; 71: 417-22. (Pubitemid 24310023)
12. Rosenberg GA, Estrada E Y, Dencoff JE, et al. Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier (BBB): an expanded therapeutic window. Brain Res 1995; 703: 151-5. (Pubitemid 3013581)
13. Rosenberg GA, Dencoff JE, Correa N, Jr, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to BBB injury. Neurology 1996; 46: 1626-32. (Pubitemid 26185784)
14. Rosenberg GA, Estrada EY, Dencoff JE. MMPs and TIMPs are associated with BBB opening after reperfusion in rat brain. Stroke 1998; 29: 2189-95. (Pubitemid 28443538)
15. Noble LJ, Donovan F, Igarashi T, et al. MMPs limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002; 22: 7526-35. (Pubitemid 35386354)
16. Gasche Y, Copin JC, Sugawara T, et al. MMP inhibition prevents oxidative stress-associated BBB disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001; 21: 1393-400. (Pubitemid 33120943)
17. Kim GW, Gasche Y, Grzeschik S, et al. Neurodegeneration in stri-atum induced by the mitochondrial toxin 3-nitropropionic acid: role of MMP-9 in early BBB disruption? J Neurosci 2003; 23: 8733-42. (Pubitemid 37176654)
18. Gijbels K, Masure S, Carton H, et al. Gelatinase in the cerebrospi-nal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
19. Gijbels K, Proost P, Masure S, et al. Gelatinase B is present in the cere-brospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36: 432-40. (Pubitemid 23326323)
20. Chandler S, Coates R, Gearing A, et al. MMPs degrade myelin basic protein. Neurosci Lett 1995; 201: 223-6.
21. Anthony DC, Miller KM, Fearn S, et al. MMP expression in an experimentally induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998; 87: 62-72. (Pubitemid 28319845)
22. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloprotein-ase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-32. (Pubitemid 32904971)
23. Hsu JY, McKeon R, Goussev S, et al. MMP-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 2006; 26: 9841-50. (Pubitemid 44477146)
24. Ogier C, Bernard A, Chollet AM, et al. MMP-2 regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006; 54: 272-84. (Pubitemid 44316232)
25. Takenaga K, Kozlova EN. Role of intracellular S100A4 for migration of rat astrocytes. Glia 2006; 53: 313-21. (Pubitemid 43221352)
26. Sappino AP, Madani R, Huarte J, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993;92:679-85. (Pubitemid 23262385)
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. (Pubitemid 29084777)
28. East E, Baker D, Pryce G, et al. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 2005;167:545-54. (Pubitemid 43026108)
29. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996;16:360-6. (Pubitemid 26125324)
30. Klironomos G, Karadimas S, Mavrakis A, et al. New experimental rabbit animal model for CSM. Spinal Cord 2011; 49: 1097-102.
31. Mattson M P. NF-κ in the survival and plasticity of neurons. Neurochem Res 2005; 30: 883-93.
32. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004; 5: 146-56. (Pubitemid 38160289)
33. Ridet JL, Malhotra SK, Privat A, et al. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997; 20: 570-7. (Pubitemid 27508969)
34. Fitch MT, Doller C, Combs CK, et al. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 1999; 19: 8182-98. (Pubitemid 30226738)
35. McGraw J, Hiebert GW, Steeves JD. Modulating astrogliosis after neurotrauma. J Neurosci Res 2001; 63: 109-15. (Pubitemid 32041861)
36. Matyash M, Matyash V, Nolte C, et al. Requirement of functional ryanodine receptor type 3 for astrocyte migration. FASEB J 2005;302005; 30: 883-93.
37. Hsu JY, Bourguignon LY, Adams CM, et al. MMP-9 facilitates glial scar formation in the injured spinal cord. J Neurosci 2008; 28: 13467-77.
38. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of MMPs after spinal cord injury: relationship to revascularization and wound healing. J Neurosurg Spine 2003; 99: 188-97.
39. Muir EM, Adcock KH, Morgenstern DA, et al. MMPs and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 2002; 100: 103-17. (Pubitemid 34465583)
40. Zuo J, Ferguson TA, Hernandez YJ, et al. Neuronal MMP-2 degrades and inactivates a neuriteinhibiting chondroitin sulfate proteoglycan. J Neurosci 1998; 18: 5203-11. (Pubitemid 28311937)
41. Han YP, Tuan TL, Wu H, et al. F-α stimulates activation of pro-MMP-2 in human skin through NF-κ B mediated induction of MT1-MMP. J Cell Sci 2001; 114: 131-9. (Pubitemid 32118063)
42. Glas M, Popp B, Angele B, et al. A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis. Exp Neurol 2007; 207: 350-6. (Pubitemid 47429664)
43. Sawaya R, Rayford A, Kono S, et al. Elevated levels of plasminogen activators in the pathogenesis of delayed radiation damage in rat cervical spinal cord in vivo. Radiat Res 1994; 138: 386-91. (Pubitemid 24181222)
44. Seeds NW, Akison L, Minor K. Role of plasminogen activator in spinal cord remodeling after spinal cord injury. Respir Physiol Neurobiol 2009; 169: 141-9.
45. Vincenti MP, Coon CI, Brinckerhoff CE. NF-κ B/p50 activates an element in the distal MMP-1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 1998; 41: 1987-94. (Pubitemid 28506689)
46. Das R, Philip S, Mahabeleshwar GH, et al. Osteopontin: its role in regulation of cell motility an nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 2005; 57: 441-7. (Pubitemid 41073126)
47. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004; 4: 327-36. (Pubitemid 38797244)
48. Reuning U, Wilhelm O, Nishiguchi T, et al. Inhibition of NF-kappa B-RelA expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 1995; 23: 3887-93.
49. Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3, 3́-diindolylmethane is mediated by the NF-κ B downstream target genes MMP-9 and u-PA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67: 3310-19. (Pubitemid 46724870)
50. Liptay S, Weber CK, Ludwig L. Mitogenic and antiapoptotic role of constitutive NF-κ B/Rel activity in pancreatic cancer. Int J Cancer 2003; 105: 735-46. (Pubitemid 36706095)
51. Wu JM, Sheng H, Saxena R, et al. NF-κ B inhibition in human hepa-tocellular carcinoma and its potential as adjunct to sorafenib-based therapy. Cancer Lett 2009; 278: 145-55.